PIC-Nal Nanoliposome Formulation for EGFR-Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current photoimmunotherapy approaches face challenges in achieving sufficient uptake of photo-immunoconjugates (PIC) in cancer cells, particularly for EGFR-overexpressing tumors, due to a trade-off between selectivity and uptake efficiency, which limits their therapeutic efficacy.
Innovation Solution
A novel photo-immunoconjugate-nanoliposome formulation (PIC-Nal) is developed, where benzoporphyrin derivative (BPD) photosensitizers are conjugated to cetuximab and tethered onto nanoliposomes, enhancing intracellular delivery and photoimmunotherapy efficacy by leveraging the 'carrier effect' and targeting multiple cellular regions simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If photo-immunoconjugates (PIC) are designed with high selectivity for EGFR-targeting, then tumor-specificity is improved, but intracellular uptake efficiency deteriorates
Solution Approach 1:
The patent merges the photo-immunoconjugate (PIC) with a nanoliposome carrier to create a hybrid formulation (PIC-Nal). This combination allows the PIC to maintain its EGFR-targeting selectivity while the nanoliposome carrier enhances intracellular uptake through carrier-mediated endocytosis, thereby resolving the contradiction between specificity and uptake efficiency
Solution Approach 2:
The nanoliposome acts as an intermediary carrier that facilitates the entry of PIC into cancer cells. The liposome carrier mediates the delivery process by fusing with cellular membranes or being internalized via endocytosis, thereby improving uptake efficiency without compromising the EGFR-targeting capability of the attached PIC
2Ease of operation
If conventional photoimmunotherapy is used, then treatment simplicity is maintained, but therapeutic efficacy deteriorates due to insufficient PIC uptake
Solution Approach 1:
The formulation merges the therapeutic benefits of photoimmunotherapy with the delivery advantages of nanoliposome technology. This hybrid approach maintains the simplicity of photoimmunotherapy administration while significantly enhancing therapeutic efficacy through improved intracellular delivery of the photosensitizer
3Reliability
If multiple therapeutic agents are co-delivered to target different cellular regions, then therapeutic efficacy is improved, but formulation complexity increases
Solution Approach 1:
The nanoliposome formulation is designed as a universal multi-functional platform that can simultaneously carry and deliver multiple therapeutic agents (PIC and irinotecan) to different cellular targets. The single formulation structure performs multiple functions: EGFR targeting via PIC, photodynamic therapy via BPD, and chemotherapy via irinotecan release, thereby improving efficacy without proportionally increasing complexity
Solution Approach 2:
The formulation uses a nested structure where the photo-immunoconjugate is tethered onto the surface of the nanoliposome, and irinotecan is encapsulated within the liposome core. This nested arrangement allows multiple therapeutic agents to be delivered through a single formulation entity, achieving multi-target therapy while maintaining formulation manageability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PIC-Nal formulation achieves higher intracellular BPD concentrations and enhanced phototoxicity in EGFR-high cancer cells, while maintaining selectivity, thereby improving treatment outcomes by synergistically targeting EGFR, mitochondria, and DNA with cetuximab, BPD, and irinotecan.
Implementation Method 1
Photoimmunotherapy (PIT) employs antibody-photosensitizer conjugate (photo-immunoconjugate, PIC) and harmless near-infrared light (λ=600-900 nm) to induce reactive oxygen species (ROS)-mediated (e.g., 1O2, O2·−, ·OH) tumor destruction
Data Source
AI summary
The present disclosure relates to photo-immunoconjugate formulations comprising a nanoparticle carrier comprising first and second therapeutic agents coupled to the nanoparticle carrier, and a photosensitizer molecule coupled to the first therapeutic agent or the nanoparticle carrier, and methods of treating cancer via administration of the photo-immunoconjugate formulations.